temozolomide has been researched along with Dysplastic Nevus Syndrome, Hereditary in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the activity and safety of camrelizumab (an anti-programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) and temozolomide as first-line treatment in patients with advanced acral melanoma." | 9.69 | Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial. ( Bai, X; Cheng, F; Chi, Z; Cui, C; Dai, J; Duan, R; Guo, J; Kong, Y; Li, C; Li, J; Li, S; Lian, B; Mao, L; Pang, Z; Sheng, X; Si, L; Tang, B; Wang, X; Wei, X; Wu, X; Xia, F; Xu, H; Yan, X; Yang, Y; Zhang, C; Zhou, L, 2023) |
| " The authors hereby, evaluated the use of temozolomide (TMZ) for treating metastatic melanoma compared to dacarbazine (DTIC), the effectiveness of TMZ for treating brain metastases, as well as TMZ resistance and how the efficacy of TMZ in malignant melanoma can be increased." | 8.91 | Temozolomide for Treating Malignant Melanoma. ( Hou, XY; Jiang, G; Li, RH; Liu, WL; Liu, YQ; Tang, JQ; Yang, CS, 2015) |
| "To assess the efficacy of single-agent temozolomide, a standard agent is used for metastatic melanoma in late adjuvant chemotherapy for cutaneous melanoma." | 8.02 | Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. ( Erturk, K; Tas, F, 2021) |
| "To investigate the predictive and prognostic value of O(6) -methylguanine DNA methyltransferase (MGMT) inactivation by analyses of promoter methylation in pretreatment tumor biopsies from patients with cutaneous melanoma treated with dacarbazine (DTIC) or temozolomide (TMZ) were performed." | 7.81 | MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. ( Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Jewell, R; Johansson, H; Lindén, D; Lindholm, C; Newton-Bishop, J; Snowden, H; Stierner, U; Tuominen, R; van den Oord, JJ; Walker, C; Wolter, P, 2015) |
| "To investigate the activity and safety of camrelizumab (an anti-programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) and temozolomide as first-line treatment in patients with advanced acral melanoma." | 5.69 | Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial. ( Bai, X; Cheng, F; Chi, Z; Cui, C; Dai, J; Duan, R; Guo, J; Kong, Y; Li, C; Li, J; Li, S; Lian, B; Mao, L; Pang, Z; Sheng, X; Si, L; Tang, B; Wang, X; Wei, X; Wu, X; Xia, F; Xu, H; Yan, X; Yang, Y; Zhang, C; Zhou, L, 2023) |
| " The authors hereby, evaluated the use of temozolomide (TMZ) for treating metastatic melanoma compared to dacarbazine (DTIC), the effectiveness of TMZ for treating brain metastases, as well as TMZ resistance and how the efficacy of TMZ in malignant melanoma can be increased." | 4.91 | Temozolomide for Treating Malignant Melanoma. ( Hou, XY; Jiang, G; Li, RH; Liu, WL; Liu, YQ; Tang, JQ; Yang, CS, 2015) |
| "To assess the efficacy of single-agent temozolomide, a standard agent is used for metastatic melanoma in late adjuvant chemotherapy for cutaneous melanoma." | 4.02 | Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. ( Erturk, K; Tas, F, 2021) |
| "To investigate the predictive and prognostic value of O(6) -methylguanine DNA methyltransferase (MGMT) inactivation by analyses of promoter methylation in pretreatment tumor biopsies from patients with cutaneous melanoma treated with dacarbazine (DTIC) or temozolomide (TMZ) were performed." | 3.81 | MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma. ( Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Jewell, R; Johansson, H; Lindén, D; Lindholm, C; Newton-Bishop, J; Snowden, H; Stierner, U; Tuominen, R; van den Oord, JJ; Walker, C; Wolter, P, 2015) |
| "In the present study we collected fresh-frozen pretreatment lymph-node metastasis samples (n=14) from melanoma patients with differential response to dacarbazine (DTIC) or temozolomide (TMZ) chemotherapy, to identify proteins with an impact on treatment response." | 3.80 | Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance. ( Azimi, A; Egyházi Brage, S; Frostvik Stolt, M; Hansson, J; Hertzman Johansson, C; Lehtiö, J; Pernemalm, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lian, W | 1 |
| Zheng, X | 1 |
| Mao, L | 1 |
| Lian, B | 1 |
| Li, C | 1 |
| Bai, X | 1 |
| Zhou, L | 1 |
| Cui, C | 1 |
| Chi, Z | 1 |
| Sheng, X | 1 |
| Wang, X | 1 |
| Tang, B | 1 |
| Yan, X | 1 |
| Li, S | 1 |
| Kong, Y | 1 |
| Dai, J | 1 |
| Wei, X | 1 |
| Li, J | 1 |
| Duan, R | 1 |
| Xu, H | 1 |
| Wu, X | 1 |
| Yang, Y | 1 |
| Cheng, F | 1 |
| Zhang, C | 1 |
| Xia, F | 1 |
| Pang, Z | 1 |
| Guo, J | 1 |
| Si, L | 1 |
| Tas, F | 1 |
| Erturk, K | 1 |
| Azimi, A | 1 |
| Pernemalm, M | 1 |
| Frostvik Stolt, M | 2 |
| Hansson, J | 2 |
| Lehtiö, J | 1 |
| Egyházi Brage, S | 2 |
| Hertzman Johansson, C | 2 |
| Tuominen, R | 1 |
| Jewell, R | 1 |
| van den Oord, JJ | 1 |
| Wolter, P | 1 |
| Stierner, U | 1 |
| Lindholm, C | 1 |
| Lindén, D | 1 |
| Johansson, H | 1 |
| Walker, C | 1 |
| Snowden, H | 1 |
| Newton-Bishop, J | 1 |
| Li, RH | 1 |
| Hou, XY | 1 |
| Yang, CS | 1 |
| Liu, WL | 1 |
| Tang, JQ | 1 |
| Liu, YQ | 1 |
| Jiang, G | 1 |
1 review available for temozolomide and Dysplastic Nevus Syndrome, Hereditary
| Article | Year |
|---|---|
Temozolomide for Treating Malignant Melanoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Melanoma; Melanoma, Cutaneo | 2015 |
1 trial available for temozolomide and Dysplastic Nevus Syndrome, Hereditary
| Article | Year |
|---|---|
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Melanoma; Melanoma, Cutaneous Malignan | 2023 |
4 other studies available for temozolomide and Dysplastic Nevus Syndrome, Hereditary
| Article | Year |
|---|---|
Identification and validation of TME-related signatures to predict prognosis and response to anti-tumor therapies in skin cutaneous melanoma.
Topics: Carrier Proteins; Cisplatin; Humans; Melanoma; Melanoma, Cutaneous Malignant; Skin Neoplasms; Temozo | 2023 |
Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Follow-Up Studies; H | 2021 |
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.
Topics: Adult; Aged; Antineoplastic Agents; Cystatin B; Dacarbazine; Drug Resistance, Neoplasm; Factor XIII; | 2014 |
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Daca | 2015 |